IP Verse

Conjugation Process Of Bacterial Polysaccharides To Carrier Proteins - EP2815762

The patent EP2815762 was granted to Glaxosmithkline on May 31, 2017. The application was originally filed on Mar 7, 2011 under application number EP14181075A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2815762

GLAXOSMITHKLINE
Application Number
EP14181075A
Filing Date
Mar 7, 2011
Status
Granted And Under Opposition
Apr 28, 2017
Grant Date
May 31, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFI PASTEUR INCSANOFI AVENTIS DEUTSCHLAND GMBHSANOFI WINTHROP INDUSTRIESFeb 28, 2018ZWICKERWITHDRAWN
SK CHEMICALSFeb 28, 2018ZWICKERWITHDRAWN
MERCK SHARP & DOHMEFeb 26, 2018VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBWITHDRAWN

Patent Citations (104) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0161188
DESCRIPTIONEP0208375
DESCRIPTIONEP0281673
DESCRIPTIONEP0372501
DESCRIPTIONEP0378881
DESCRIPTIONEP0427347
DESCRIPTIONEP0471177
DESCRIPTIONEP0477508
DESCRIPTIONEP0497524
DESCRIPTIONEP0497525
DESCRIPTIONEP0594610
DESCRIPTIONEP1092444
DESCRIPTIONUS2007184072
DESCRIPTIONUS4057685
DESCRIPTIONUS4235877
DESCRIPTIONUS4365170
DESCRIPTIONUS4459286
DESCRIPTIONUS4596556
DESCRIPTIONUS4673574
DESCRIPTIONUS4709017
DESCRIPTIONUS4790824
DESCRIPTIONUS4808700
DESCRIPTIONUS4940460
DESCRIPTIONUS4941880
DESCRIPTIONUS4950740
DESCRIPTIONUS5064413
DESCRIPTIONUS5312335
DESCRIPTIONUS5334144
DESCRIPTIONUS5339163
DESCRIPTIONUS5383851
DESCRIPTIONUS5466220
DESCRIPTIONUS5480381
DESCRIPTIONUS5503627
DESCRIPTIONUS5520639
DESCRIPTIONUS5569189
DESCRIPTIONUS5599302
DESCRIPTIONUS5649912
DESCRIPTIONUS5704911
DESCRIPTIONUS5766608
DESCRIPTIONUS5843464
DESCRIPTIONUS5843711
DESCRIPTIONUS5893397
DESCRIPTIONUS5917017
DESCRIPTIONUS5993412
DESCRIPTIONUS6455673
DESCRIPTIONWO0010599
DESCRIPTIONWO0037105
DESCRIPTIONWO0056360
DESCRIPTIONWO0061761
DESCRIPTIONWO0113977
DESCRIPTIONWO0172337
DESCRIPTIONWO02091998
DESCRIPTIONWO0209746
DESCRIPTIONWO2006067632
DESCRIPTIONWO9101146
DESCRIPTIONWO9303761
DESCRIPTIONWO9315760
DESCRIPTIONWO9317712
DESCRIPTIONWO9403208
DESCRIPTIONWO9405325
DESCRIPTIONWO9508348
DESCRIPTIONWO9629094
DESCRIPTIONWO9634960
DESCRIPTIONWO9701638
DESCRIPTIONWO9713537
DESCRIPTIONWO9713785
DESCRIPTIONWO9732980
DESCRIPTIONWO9737705
DESCRIPTIONWO9741731
DESCRIPTIONWO9748440
DESCRIPTIONWO9818930
DESCRIPTIONWO9820734
DESCRIPTIONWO9828037
DESCRIPTIONWO9855606
DESCRIPTIONWO9858668
DESCRIPTIONWO9927961
DESCRIPTIONWO9934850
DESCRIPTIONWO9964067
OPPOSITIONEP1625850
OPPOSITIONEP2815762
OPPOSITIONUS2004213803
OPPOSITIONUS2007141084
OPPOSITIONUS2007184071
OPPOSITIONUS2007184072
OPPOSITIONUS4356170
OPPOSITIONUS4902506
OPPOSITIONUS5565204
OPPOSITIONUS5623057
OPPOSITIONWO0222168
OPPOSITIONWO2004043376
OPPOSITIONWO2005014037
OPPOSITIONWO2006082530
OPPOSITIONWO2007000322
OPPOSITIONWO2007071707
OPPOSITIONWO2008157590
OPPOSITIONWO2009000825
OPPOSITIONWO9405325
OPPOSITIONWO9605859
OPPOSITIONWO9831393
SEARCHUS2007184071
SEARCHUS4356170
SEARCHWO2006082530
SEARCHWO2007000322
SEARCHWO2007071707

Non-Patent Literature (NPL) Citations (43) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BARALDOI ET AL., INFECT IMMUN, (2004), vol. 72, pages 4884 - 7-
DESCRIPTION- CHU C. ET AL., INFECT. IMMUNITY, (1983), page 245 256-
DESCRIPTION- FALUGI ET AL., EUR J IMMUNOL, (2001), vol. 31, pages 3816 - 3824-
DESCRIPTION- GEVER ET AL., MED. MICROBIOL. IMMUNOL., (1979), vol. 165, pages 171 - 288-
DESCRIPTION- HELMINEN ME ET AL., INFECT. IMMUN., (1993), vol. 61, pages 2003 - 2010-
DESCRIPTION- KUO ET AL., INFECT IMMUN, (1995), vol. 63, pages 2706 - 13-
DESCRIPTION- SHOUSUN CHEN SZU ET AL., CARBOHYDRATE RESEARCH, (1986), vol. 152, pages 7 - 20-
DESCRIPTION- TETRAHEDRON LETTERS, (200506), vol. 46, pages 4479 - 4482-
DESCRIPTION- UCHIDA ET AL., J. BIOL. CHEM., (1973), vol. 218, pages 3838 - 3844-
OPPOSITION- "1. Functional Targets", HERMANSON, G.T., Bioconjugate Techniques, Academic Press, Inc, (19960108), pages 114 - 116, XP055470232-
OPPOSITION- "1. Functional Targets", HERMANSON, G.T., Bioconjugate Techniques, Academic Press, Inc, pages 114 - 116, XP055470232-
OPPOSITION- ANDERSON et al., "Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant", J. of Immunol., (19860815), vol. 137, no. 4, pages 1181 - 1186, XP055007229-
OPPOSITION- ANDERSON et al., "Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant", The Journal of Immunology, (19860815), vol. 137, no. 4, pages 1181 - 1186, XP055007229-
OPPOSITION- ANDERSON, P.W. et al., "Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.", J Immunol, (19890401), vol. 142, no. 7, pages 2464 - 2468, XP002913714-
OPPOSITION- ANDERSON, P.W. et al., "Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.", J Immunol, (19890407), vol. 142, pages 2464 - 2468, XP002913714-
OPPOSITION- Anonymous, "Biological Buffers", AppliChem, (20080000), pages 1 - 20, XP055591620-
OPPOSITION- Anonymous, "Room temperature", Wikipedia, (20190810), pages 1 - 3, URL: https://en.wikipedia.ortz/wiki/Room_ temperature, XP055642435-
OPPOSITION- Anonymous, "The Effect of Temperature on Rate of Reaction", LibreTexts Chemistry, pages 1 - 2, URL: https://chem.libretexts.org/Bookshelves/Physical_and_Theoretical_Chemistry_Textbook_Maps/Supplemental_Modules_(Physical_and_Theoretical_Chemistry)/Kinetics/Rate_Laws/Reaction_Mechanisms/Reaction_Mechanisms/The_Effect_of_Temperature_on_Rate_of_Reaction, XP055642431-
OPPOSITION- "chapter 11 conjugation chemistry", LEES et al., Pneumococcal Vaccines: the Impact of Conjugate Vaccine, (20080000), pages 163 - 174, XP055467636-
OPPOSITION- "Creating Specific Functionalities", HERMANSON, Bioconjugate Techniques, (20080000), pages 129 - 131, XP055467625-
OPPOSITION- KRISTIANSEN et al., "Periodate oxidation of polysaccharides for modification of chemical and physical properties", Carbohydrate Res., (20100000), vol. 345, no. 10, pages 1264 - 1271, XP027118778-
OPPOSITION- KUO et al., "Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines", Infect Immun, (19950000), vol. 63, pages 2706 - 2713, XP055033057-
OPPOSITION- "product information", Excerpt of 'PDR, (19900207), pages 880-881 - ,1431-1432, XP055467629-
OPPOSITION- "product information", PDR 63, (20081118), pages 3241 - 3247, XP055467646-
OPPOSITION- "Sigma catalogue", Biochemicals and Reagents, For Life Science Research, (20000000), page 781, XP055467643-
OPPOSITION- LEE, C.J., "Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry", Biologicals, (20020600), vol. 30, no. 2, pages 97 - 103, XP002330498
OPPOSITION- LEE, C.J., "Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry", Biologicals, (20020600), vol. 30, pages 97 - 103, XP002330498
OPPOSITION- LEE, "Quality Control of Polyvalent Pneumococcal Polysaccharide-Protein Conjugate Vaccine by Nephelometry", The International Association for Biologicals, (20020000), vol. 63, pages 97 - 103, XP002330498
OPPOSITION- KIM et al., "Monitoring activation sites on polysaccharides by GC-MS", Analytical Biochemistry, (20060830), vol. 358, pages 136 - 142, XP005694532
OPPOSITION- KIM J.S., "Monitoring activation sites on polysaccharides by GC-MS", Analytical Biochemistry, New York, (20060830), vol. 358, no. 1, pages 136 - 142, XP005694532
OPPOSITION- KIM J.S., "Monitoring activation sites on polysaccharides by GC-MS", Analytical Biochemistry, New York, (20060830), vol. 358, no. 1, pages 136 - 142, XP024942320
OPPOSITION- FRASCH C.E, "Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges", Vaccine, (20090624), vol. 27, no. 46, pages 6468 - 6470, XP026704485
OPPOSITION- FRASCH C.E, "Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges", Vaccine, (20091030), vol. 27, no. 46, pages 6468 - 6470, XP026704485
OPPOSITION- FRASCH, "Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges", Vaccine, (20090624), vol. 27, no. 46, pages 6468 - 6470, XP026704485
OPPOSITION- LAFERRIERE, C.A. et al., "The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity", Vaccine, (19971102), vol. 15, no. 2, pages 179 - 186, XP002301344
OPPOSITION- STEINHOFF, M.C. et al., "A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics", Pediatric Inf. Disease J., (19940501), vol. 13, no. 5, pages 368 - 372, XP000600692
OPPOSITION- RICHARDS, J.C. et al., "Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23)", Biochem Cell Biol, (19880700), vol. 66, no. 7, pages 758 - 771, XP009155178
OPPOSITION- RICHARDS, J.C. et al., "Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23)", Biochem Cell Biol, (19880700), vol. 66, pages 758 - 771, XP009155178
OPPOSITION- PEETERS, CC et al., "Preparation of polysaccharide-conjugate vaccines", Methods in Molecular Medicine?, (20030200), vol. 87, pages 153 - 173, XP002310929
OPPOSITION- PEETERS, CC et al., "Preparation of polysaccharide-conjugate vaccines", PEETERS, CC et al., Robinson A., Hudson M.J., Cranage M.P., Vaccine Protocols. Methods in Molecular Medicine?, Humana Press, (20030201), vol. 87, pages 153 - 173, ISBN 978-1-58829-140-0, XP002310929
SEARCH- ANDERSON ET AL, "Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant.", THE JOURNAL OF IMMUNOLOGY, (19860801), vol. 137, no. 4, ISSN 0022-1767, pages 1181 - 1186, XP055007229 [Y] 1-3,9-12 * the whole document *-
SEARCH- KIM J S ET AL, "Monitoring activation sites on polysaccharides by GC-MS", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 358, no. 1, doi:10.1016/J.AB.2006.08.016, ISSN 0003-2697, (20061101), pages 136 - 142, (20061101), XP024942320 [Y] 1-3,9-12 * the whole document *
SEARCH- STEINHOFF M C ET AL, "A RANDOMIZED COMPARISON OF THREE BIVALENT STREPTOCOCCUS PNEUMONIAE GLYCOPROTEIN CONJUGATE VACCINES IN YOUNG CHILDREN: EFFECT OF POLYSACCHARIDE SIZE AND LINKAGE CHARACTERISTICS", THE PEDIATRIC INFECTIOUS DISEASE JOURNAL, LIPPINCOTT WILLIAMS & WILKINS, US, (19940501), vol. 13, no. 5, doi:10.1097/00006454-199405000-00007, ISSN 0891-3668, pages 368 - 372, XP000600692 [Y] 1-3,9-12 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents